What to make of this whole Sarepta situation

Sarepta Therapeutics’ shares are down about 15% since last week after a confusing entry in an FDA database snowballed into concerns that the company’s next big idea might get derailed by a safety problem.

STAT’s Adam Feuerstein sat down to unpack the knowns, unknowns, and unknown unknowns tied to Sarepta’s gene therapy for Duchenne muscular dystrophy. That means an explanation of the FDA angle, a discussion of who knew what when, and all-important context for a fast-moving space.

Some highlights: Yes, this is serious. No, it’s not damning. Yes, Sarepta found out when you did. No, this isn’t the work of a dastardly cabal of short-sellers bent on keeping a good company down.

Read more.